| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 06/15/2000 | WO2000034248A1 New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| 06/15/2000 | WO2000034230A1 4-3-substituted-amino-cyclobut-3-ene-1,2-diones and use for influencing smooth muscle contraction |
| 06/15/2000 | WO2000034228A1 Ion channel modulating agents |
| 06/15/2000 | WO2000033834A1 Use of isatin derivatives as ion channel activating agents |
| 06/15/2000 | WO1999038503A8 Pharmacological uses of optically pure (+)-bupropion |
| 06/15/2000 | CA2352740A1 Procollagen c-proteinase inhibitors |
| 06/15/2000 | CA2351060A1 Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 06/15/2000 | CA2351059A1 Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 06/15/2000 | CA2350888A1 4-3-substituted-amino-cyclobut-3-ene-1,2-diones and use for influencing smooth muscle contraction |
| 06/15/2000 | CA2349616A1 New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| 06/14/2000 | EP1007563A1 Hm74a receptor |
| 06/14/2000 | EP1007539A1 Secreted proteins and polynucleotides encoding them |
| 06/14/2000 | EP1007526A1 Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands |
| 06/14/2000 | EP0901463B1 Glycerolipidic compounds used for the transfer of an active substance into a target cell |
| 06/14/2000 | EP0822812A4 Topical treatment and/or prevention of sagging subcutaneous muscle and overlying cutaneous tissue using acetylcholine precursors and catecholamines |
| 06/08/2000 | WO2000032634A1 Humanized antibodies to gamma-interferon |
| 06/08/2000 | WO2000032620A1 Gamma-ketoacid tetrapeptides as inhibitors of caspase-3 |
| 06/08/2000 | WO2000032600A1 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives |
| 06/08/2000 | WO2000032189A1 Celecoxib compositions |
| 06/08/2000 | WO2000032175A2 METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY |
| 06/08/2000 | WO2000015245A3 Stable liquid formulations of botulinum toxin |
| 06/08/2000 | WO2000009086A3 Protected one-vial formulation for nucleic acid molecules, methods of making the same by in-line mixing, and related products and methods |
| 06/08/2000 | CA2353079A1 Gamma-ketoacid tetrapeptides as inhibitors of caspase-3 |
| 06/08/2000 | CA2350597A1 Methods and compositions for restoring conformational stability of a protein of the p53 family |
| 06/08/2000 | CA2342621A1 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives |
| 06/07/2000 | EP1005867A2 Botulinum toxins for modulating cholinergic controlled secretions |
| 06/07/2000 | EP1005459A1 Substituted isoquinolines as anticonvulsivants |
| 06/07/2000 | EP1005371A2 Method and food product for increasing muscle protein and reducing fat in animals |
| 06/07/2000 | CN1255917A Anti-convulsant isoquinolyl-benzamide derivatives |
| 06/06/2000 | US6071516 Administering normal gamma-globulin |
| 06/02/2000 | WO2000031263A2 Gtpase associated proteins |
| 06/02/2000 | WO2000031100A2 Benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 06/02/2000 | WO2000031096A1 Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 06/02/2000 | WO2000031095A2 Benzylmaltotriosides as inhibitors of smooth muscle cell proliferation |
| 06/02/2000 | WO2000030644A1 Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline |
| 06/02/2000 | WO2000030643A1 Novel therapeutic application of nicergoline |
| 06/02/2000 | WO2000030642A1 Use of nicergoline for treating spasmodism |
| 06/02/2000 | WO2000030634A1 Oral creatine supplementation for treating or preventing muscle disuse syndrome |
| 06/02/2000 | WO2000030615A1 Method of preparing stable suspensions of insoluble microparticles |
| 06/02/2000 | CA2351691A1 Oral creatine supplementation for treating or preventing muscle disuse syndrome |
| 06/02/2000 | CA2351361A1 Gtpase associated proteins |
| 06/02/2000 | CA2350759A1 Benzylmaltotriosides as inhibitors of smooth muscle cell proliferation |
| 06/02/2000 | CA2350753A1 Benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 06/02/2000 | CA2350066A1 Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 05/31/2000 | EP1003857A2 Secreted proteins and polynucleotides encoding them |
| 05/31/2000 | EP1003784A1 Novel peptides and polypeptides useful for regenerating the nervous system |
| 05/31/2000 | EP1003763A1 83 human secreted proteins |
| 05/31/2000 | EP1003749A1 8-SUBSTITUTED-9H-1,3-DIOXOLO/4,5-h/2,3/BENZODIAZEPINE DERIVATES, AS AMPA/KAINATERECEPTOR INHIBITORS |
| 05/31/2000 | EP1003740A2 Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagoists |
| 05/31/2000 | EP1003540A1 $g(b)2-ADRENERGIC RECEPTOR AGONISTS |
| 05/31/2000 | EP1003505A1 Heterocyclic vinylethers against neurological disorders |
| 05/31/2000 | EP1003491A1 Use of antagonists or partial agonists of the vanilloid receptor complexes for treating neurodegenerative diseases |
| 05/31/2000 | CN1255124A Substituted isoquinoline derivatives and their use as anticonulsants |
| 05/31/2000 | CN1255065A Medicinal preparation containing lipophilicity inert gas |
| 05/25/2000 | WO2000029623A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 05/25/2000 | WO2000029583A2 Immunoglobulin superfamily proteins |
| 05/25/2000 | WO2000029569A1 Methods of diagnosing or treating neurological diseases |
| 05/25/2000 | WO2000029564A2 Human glycine transporter type 2 |
| 05/25/2000 | WO2000029371A1 Excitatory amino acid receptor modulators |
| 05/25/2000 | WO2000028992A1 Riluzole and alpha-tocopherol combination |
| 05/25/2000 | WO2000015798A3 Mammalian transforming growth factor beta - 9 (ztgfss9) |
| 05/25/2000 | CA2351576A1 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 05/25/2000 | CA2350698A1 Human glycine transporter type 2 |
| 05/25/2000 | CA2350532A1 Excitatory amino acid receptor modulators |
| 05/24/2000 | EP1002862A1 Methods of diagnosing or treating neurological diseases |
| 05/24/2000 | EP1002534A1 Bis-Staurosporine and K-252a derivatives |
| 05/24/2000 | EP1002532A1 Prevention of aging effects and treatment of muscle atrophy |
| 05/24/2000 | EP1002068A1 Mutations in the myostatin gene cause double-muscling in mammals |
| 05/24/2000 | EP1001970A1 Dipeptide derivatives as growth hormone secretagogues |
| 05/24/2000 | EP1001956A1 New 2,3-benzodiazepine derivatives |
| 05/18/2000 | WO2000028035A1 CHEMOKINE β-7 |
| 05/18/2000 | WO2000027808A1 N-arylsulfonyl amino acid omega amides |
| 05/18/2000 | WO2000027805A1 Substituted 3,3-diamino-2-propenenitriles, their preparation and use |
| 05/18/2000 | WO2000027377A2 Phosphinate peptide analogs for the treatment of fibrotic disorders |
| 05/18/2000 | DE19852508A1 Use of fat-soluble substance obtained from avocado oil as an antiphlogistic, antirheumatic, antimycotic or antiscabiotic agent, or as a toothpaste, lipstick, leather treatment agent or in bandages |
| 05/18/2000 | CA2350771A1 Chemokine .beta.-7 |
| 05/18/2000 | CA2348934A1 Phosphinate peptide analogs for the treatment of fibrotic disorders |
| 05/17/2000 | EP1000927A2 Excitatory amino acid receptor modulators |
| 05/17/2000 | CN1253547A 1,4-substituted cyclic amine derivatives |
| 05/17/2000 | CN1253544A Solid compositions suitable for oral administration comprising L-carnitine or alkanoyl-L-carnitine magnesium fumarate |
| 05/16/2000 | US6063378 Therapeutic agent for herniated intervertebral disc |
| 05/11/2000 | WO2000026372A1 Myosin heavy chain homolog |
| 05/11/2000 | WO2000026252A1 Compounds with growth hormone releasing properties |
| 05/11/2000 | WO2000026245A2 Human membrane transport proteins |
| 05/11/2000 | WO2000026212A1 Chromenone and chromanone derivatives as integrin inhibitors |
| 05/11/2000 | WO2000026208A1 N-oxides of heterocyclic compounds with tnf and pde-iv inhibiting activity |
| 05/11/2000 | WO2000026167A1 Vitamin d analogues |
| 05/11/2000 | WO2000025793A1 Compositions for the treatment and prevention of neurological and pathopsychological diseases |
| 05/11/2000 | WO2000025787A1 Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same |
| 05/11/2000 | WO2000025774A1 Benzamide potassium channel inhibitors |
| 05/11/2000 | WO2000025770A1 Carbocyclic potassium channel inhibitors |
| 05/11/2000 | WO2000007565A3 Methods of ophthalmic administration |
| 05/11/2000 | DE19851184A1 N-Arylsulfonyl-aminosäure-omega-amide N-arylsulfonyl-amino-omega-amides |
| 05/11/2000 | CA2350052A1 Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same |
| 05/11/2000 | CA2349818A1 Membrane transport proteins |
| 05/11/2000 | CA2349212A1 Myosin heavy chain homolog |
| 05/11/2000 | CA2348446A1 Benzamide potassium channel inhibitors |
| 05/11/2000 | CA2347102A1 Compounds with growth hormone releasing properties |
| 05/11/2000 | CA2312430A1 N-oxides of heterocyclic compounds with tnf and pde-iv inhibiting activity |
| 05/10/2000 | EP0998494A1 Pompilid wasp-derived neuropeptides |